CN117794543A - Setd2抑制剂的联合治疗 - Google Patents

Setd2抑制剂的联合治疗 Download PDF

Info

Publication number
CN117794543A
CN117794543A CN202280054248.9A CN202280054248A CN117794543A CN 117794543 A CN117794543 A CN 117794543A CN 202280054248 A CN202280054248 A CN 202280054248A CN 117794543 A CN117794543 A CN 117794543A
Authority
CN
China
Prior art keywords
alkyl
group
cycloalkyl
hydroxy
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280054248.9A
Other languages
English (en)
Chinese (zh)
Inventor
玛丽亚·亚历山德拉·雷蒙迪
詹尼弗·安妮·托特曼
维尼·莫特瓦尼
凯瑟琳·路易丝·科斯莫普洛斯
多萝西·布拉奇
丹尼尔·T·德兰斯菲尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epizyme Inc
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of CN117794543A publication Critical patent/CN117794543A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280054248.9A 2021-06-09 2022-06-08 Setd2抑制剂的联合治疗 Pending CN117794543A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208882P 2021-06-09 2021-06-09
US63/208,882 2021-06-09
PCT/US2022/032718 WO2022261243A1 (en) 2021-06-09 2022-06-08 Combination therapies with setd2 inhibitors

Publications (1)

Publication Number Publication Date
CN117794543A true CN117794543A (zh) 2024-03-29

Family

ID=84425539

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280054248.9A Pending CN117794543A (zh) 2021-06-09 2022-06-08 Setd2抑制剂的联合治疗

Country Status (10)

Country Link
US (1) US20240299352A1 (enExample)
EP (1) EP4351552A4 (enExample)
JP (1) JP2024522184A (enExample)
KR (1) KR20240019241A (enExample)
CN (1) CN117794543A (enExample)
AU (1) AU2022288073A1 (enExample)
CA (1) CA3221071A1 (enExample)
IL (1) IL308868A (enExample)
MX (1) MX2023014663A (enExample)
WO (1) WO2022261243A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272379B2 (en) 2017-08-14 2025-11-01 Epizyme Inc Methods of treating cancer by inhibiting setd2
JP7627209B2 (ja) 2018-08-14 2025-02-05 エピザイム，インコーポレイティド 置換インドール及びその使用方法
CN121695288A (zh) 2020-02-19 2026-03-20 Epizyme股份有限公司 Setd2抑制剂和相关方法和用途，包括组合疗法
WO2025034951A1 (en) * 2023-08-09 2025-02-13 Enanta Pharmaceuticals, Inc. Pharmaceutical compounds and compositions as c-kit kinase inhibitors
TW202532067A (zh) * 2023-12-13 2025-08-16 大陸商正大天晴藥業集團股份有限公司 含有吡唑環及雙環雜芳基的化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9446064B2 (en) * 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
WO2015150097A1 (en) * 2014-04-04 2015-10-08 Iomet Pharma Ltd Indole derivatives for use in medicine
US20170232030A1 (en) * 2014-08-13 2017-08-17 Epizyme, Inc. Combination therapy for treating cancer
US9717745B2 (en) * 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
IL272379B2 (en) * 2017-08-14 2025-11-01 Epizyme Inc Methods of treating cancer by inhibiting setd2
JP7627209B2 (ja) * 2018-08-14 2025-02-05 エピザイム，インコーポレイティド 置換インドール及びその使用方法
WO2020112872A1 (en) * 2018-11-30 2020-06-04 Epizyme, Inc. Methods of treating whsc1-overexpressing cancers by inhibiting setd2
CN121695288A (zh) * 2020-02-19 2026-03-20 Epizyme股份有限公司 Setd2抑制剂和相关方法和用途，包括组合疗法

Also Published As

Publication number Publication date
EP4351552A4 (en) 2025-06-18
KR20240019241A (ko) 2024-02-14
US20240299352A1 (en) 2024-09-12
JP2024522184A (ja) 2024-06-11
MX2023014663A (es) 2024-05-08
CA3221071A1 (en) 2022-12-15
AU2022288073A1 (en) 2023-12-07
WO2022261243A1 (en) 2022-12-15
IL308868A (en) 2024-01-01
EP4351552A1 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
CN115380033B (zh) Setd2抑制剂和相关方法和用途，包括组合疗法
CA2926328C (en) Substituted quinazolinyl and quinolinyl derivatives and pharmaceutical compositions thereof useful as inhibitors of kras g12c
JP7627209B2 (ja) 置換インドール及びその使用方法
RU2326882C2 (ru) Пиримидиновые соединения, обладающие антипролиферативной активностью (ii)
AU2022288073A1 (en) Combination therapies with setd2 inhibitors
CA2982360A1 (en) Fused-tricyclic inhibitors of kras and methods of use thereof
WO2017058915A1 (en) Inhibitors of kras g12c mutant proteins
CN107108567A (zh) 极光激酶a抑制剂
KR20110089418A (ko) 트리아진, 피리미딘 및 피리딘 유사체 및 이의 치료제 및 진단 프로브로의 용도
TW202339736A (zh) 化合物及使用方法
AU2018234985B2 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
JP2018532713A (ja) Ｐｉｍキナーゼ阻害剤の塩
WO2021074251A1 (en) Pyrrolo[2,3-d]pyrimidine derivatives and their use in the treatment of cancer
JP2022515880A (ja) Ｔａｍおよびｍｅｔキナーゼの阻害薬としてのキノリン化合物
JP2021528413A (ja) Ｏｇａ阻害化合物
HK40084091A (en) Setd2 inhibitors and related methods and uses, including combination therapies
HK40027895A (en) Inhibitors of kras g12c
NZ719076B2 (en) Inhibitors of kras g12c

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination